GLP-1RA use, compared with basal insulin and DPP-4i use, was associated with lower risks for IBD and hospitalization in type 2 diabetes.

Patients with inflammatory bowel disease often have to wait a long time to find the right medicine. But the methods of a large interdisciplinary research team offer hope.

The McGill IBD Research Group, in partnership with the Montreal General Hospital Foundation, will hold its annual fundraising ...

IBD research, for all its sophistication, has been searching under the lamppost — sequencing, mapping and quantifying what can be seen. But the key may lie in the park, in the unseen intersections of ...

Use of teduglutide appeared safe for patients with short bowel syndrome, with no increased incidence of gastrointestinal ...

Doctors are alerted by digital clubbing, a bulbous swelling of fingertips, a sign known since ancient times. This often ...

Ulcerative Colitis Treatment Market To Reach $12.79 Billion By 2033 Biologics, Biosimilars & Small Molecules Rise. EINPresswire/ -- According to DataM Intelligence, the ulcerative colitis treatment ...

Treatment of significant musculoskeletal symptoms with NSAIDs may be acceptable for certain patients with inflammatory bowel disease.

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

1. Among patients with adult-onset inflammatory bowel disease (IBD), the incidence of ocular manifestations was 2.9 per 1000 person-years. 2. The incidence of ocular manifestations was higher in ...

Objectives Data on health inequalities in inflammatory bowel disease (IBD) among women of childbearing age (WCBA, 15–49 years) across different countries are lacking. We aimed to assess the global ...

The updated indications state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy. The Food ...